Updated: January 19, 2026

Valtoco Shortage: What Providers and Prescribers Need to Know in 2026

Author

Peter Daggett

Summarize with AI

Current Valtoco Availability Status (2026)
Why Retail Pharmacies Don't Stock Valtoco
Prior Authorization: What to Expect
E-Prescribing Best Practices for Valtoco
When to Consider Alternatives
How medfinder Supports Your Patients

A clinical guide for providers on Valtoco availability in 2026—what's driving pharmacy stocking issues, how to help patients access it, and when to consider alternatives.

Valtoco (diazepam nasal spray, CIV) has become an important tool in the management of seizure clusters for patients with epilepsy. However, many clinicians are hearing from patients that their pharmacy doesn't carry it—or that insurance hurdles are delaying access. This guide summarizes what neurologists, epileptologists, pediatricians, and other prescribers need to know about Valtoco availability in 2026.

Current Valtoco Availability Status (2026)

As of 2026, Valtoco (diazepam nasal spray) is not listed on the FDA Drug Shortage Database or the ASHP Drug Shortages resource. There is no active national shortage. However, "not in shortage" does not equal "widely available." Clinicians should be aware that:

Most general retail pharmacies do not stock Valtoco as a standard inventory item

Specialty pharmacies are the most reliable source for patients

Patients may need 1–5 business days for a retail pharmacy to special-order the medication

The FDA expanded approval to ages 2–5 in April 2025, potentially increasing patient demand over time

Why Retail Pharmacies Don't Stock Valtoco

Several structural factors limit retail pharmacy stocking:

Single-source manufacturer: Neurelis, Inc. is the sole manufacturer. No authorized generics exist, limiting market pressure to increase stocking volumes.

Specialty product with limited turnover: Valtoco is an intermittent-use rescue medication, not a chronic daily drug. Pharmacies that stock it may see slow turnover.

Schedule IV controlled substance requirements: DEA Schedule IV status requires additional recordkeeping and storage compliance that discourages stocking at lower-volume pharmacies.

Prior Authorization: What to Expect

Most commercial insurance plans cover Valtoco, but prior authorization (PA) is commonly required. Cigna, for example, requires PA and stipulates that the medication be prescribed by or in consultation with a neurologist. Expect to document:

Diagnosis of epilepsy with seizure clusters (acute repetitive seizures distinct from usual pattern)

Patient age and weight (for weight-based dosing documentation)

Prior trial or contraindication to other rescue medications (Diastat, Nayzilam) if required by payer step therapy

Clinical justification for nasal spray over rectal gel formulation

The myNEURELIS program (1-866-696-3873) provides PA support and can work directly with payers on your behalf. Many approvals are obtained when clinical justification is thorough.

E-Prescribing Best Practices for Valtoco

To minimize dispensing delays, consider e-prescribing Valtoco directly to a specialty pharmacy that reliably stocks the medication:

PharmaCord Pharmacy — NABP 1836191 (preferred myNEURELIS dispensing pharmacy; note all myNEURELIS PAP prescriptions must be e-scribed here per Board of Pharmacy regulations in applicable states)

Confirm the patient's insurance and dose (5 mg, 10 mg, 15 mg, or 20 mg dose kit based on weight and age) before prescribing

Include quantity (number of kits), number of refills, and seizure action plan instructions in the prescription notes

When to Consider Alternatives

If Valtoco is unavailable or insurance approval is significantly delayed, consider these alternatives while pursuing access to Valtoco:

Nayzilam (midazolam nasal spray): For patients ages 12 and older. Similar nasal spray delivery. Allows one episode every 3 days (vs. Valtoco's 5 days).

Diazepam rectal gel (generic Diastat): Available in generic; approved for ages 2+; widely stocked; significantly more affordable. Less convenient route of administration.

Oral lorazepam: A benzodiazepine widely available in generic form; may serve as a bridge rescue for patients who can take oral medication during or after a seizure.

How medfinder Supports Your Patients

Recommending medfinder to your patients with Valtoco prescriptions can reduce the burden on your staff and help patients locate their medication faster. medfinder calls pharmacies near the patient on their behalf and texts them results, saving the patient from having to make dozens of calls—particularly valuable for specialty seizure medications like Valtoco.

Frequently Asked Questions

Yes, most commercial insurance plans require prior authorization for Valtoco. Cigna's PA policy, for example, requires that Valtoco be prescribed by or in consultation with a neurologist and that the patient has a documented epilepsy diagnosis with seizure clusters. The myNEURELIS program (1-866-696-3873) provides PA support.

For patients using the myNEURELIS support program, e-prescriptions should be sent to PharmaCord Pharmacy (NABP 1836191). This specialty pharmacy reliably stocks Valtoco. For patients using commercial insurance without the PAP, consider e-prescribing to a local specialty pharmacy confirmed to carry the medication.

Typically: confirmed epilepsy diagnosis with documented seizure clusters distinct from usual pattern, patient age and weight for dosing, clinical justification for nasal spray over rectal gel, and sometimes evidence of prior trial or failure of other rescue medications. Complete documentation on the first submission improves approval rates.

Yes. In April 2025, the FDA expanded Valtoco's approval to include children ages 2 to 5. Dosing for children ages 2-5 is weight-based (0.5 mg/kg), and the 20 mg dose was not clinically evaluated in this age group. The drug is not approved for neonates or infants.

myNEURELIS is Neurelis' patient support program for Valtoco patients. It provides insurance verification, prior authorization support, copay card enrollment (as low as $20 for commercially insured patients), a Patient Assistance Program for uninsured patients, nurse educator calls, and pharmacy referrals. Contact: 1-866-696-3873.

Medfinder Editorial Standards

Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.

Read our editorial standards